Attached files
file | filename |
---|---|
EX-3.2 - EXHIBIT 3.2 - Fibrocell Science, Inc. | c10249exv3w2.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): NOVEMBER 18, 2010
FIBROCELL SCIENCE, INC.
(Exact name of registrant as specified in its charter)
DELAWARE | 001-31564 | 87-0458888 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
405 EAGLEVIEW BLVD., EXTON, PA |
19341 |
|
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code: (484) 713-6000
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01. Entry into a Material Definitive Agreement
November Securities Purchase Agreements
On November 8 and November 17, 2010, Fibrocell Science, Inc. (the Company) entered into
Securities Purchase Agreements (the Purchase Agreements) with certain accredited investors (the
Purchasers), pursuant to which the Company agreed to sell to the Purchasers in the aggregate: (i)
775 shares of Series B Convertible Preferred Stock, with a par value of $0.001 per share and a
stated value of $1,000 per share (Series B Preferred), and (ii) warrants to purchase 1,291,667
shares of Company common stock (Common Stock) at an exercise price of $0.8054 per share (the
Warrants) (the Transactions).
The aggregate purchase price to be paid by the Purchasers for the Series B Preferred and the
Warrants will be $775,000 (representing $1,000 for each share of Series B Preferred together with
Warrants). The Company intends to use the proceeds for working capital purposes.
Viriathus Capital LLC and John Carris Investments LLC were co-placement agents for the
Transactions, and will receive cash compensation of $61,997 and warrants to purchase 103,329 shares
of Common Stock at an exercise price of $0.60 per share (assuming all subscription proceeds are
received in the Transactions).
The form of the Purchase Agreements used for the Transactions is attached hereto as Exhibit
10.1.
Terms of the Series B Preferred
To designate and establish the shares of Series B Preferred, the Companys Board of Directors
(the Board) approved, and on July 16, 2010, the Company filed with the Delaware Secretary of
State, a Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible
Preferred Stock (the Certificate of Designation).
Dividends; Rank; Liquidation
Holders of the Series B Preferred are entitled to receive cumulative dividends at the rate per
share (as a percentage of the stated value per share) of 6% per annum (subject to increase in
certain circumstances), payable quarterly in arrears on January 15, April 15, July 15 and October
15, beginning on January 15, 2011. The dividends are payable in cash, or at the Companys option,
in duly authorized, validly issued, fully paid and non-assessable shares of Common Stock equal to
110% of the cash dividend amount payable on the dividend payment date, or a combination thereof;
provided that the Company may not pay the dividends in shares of Common Stock unless the Company
meets certain conditions described in the Certificate of Designation, including that the resale of
the shares has been registered under the Securities Act of 1933, as amended (the Securities Act)
or is otherwise eligible to be resold pursuant to an exemption from the Securities Act. If the
Company pays the dividend in shares of Common Stock, the Common Stock will be valued for such
purpose at 80% of the average of the volume weighted average price for the 10 consecutive trading
days ending on the trading day that is immediately prior to the dividend payment date
The Series B Preferred ranks senior to all shares of Common Stock, and junior to the Companys
Series A Convertible Preferred Stock.
Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or
involuntary, the holders of the Series B Preferred shall be entitled to receive out of the assets,
whether capital or surplus, of the Company an amount equal to the stated value of the Common Stock,
plus any accrued and unpaid dividends thereon and any other fees or liquidated damages then due and
owing thereon under the Certificate of Designation, for each share of Series B Preferred before any
distribution or payment shall be made to the holders of any junior securities, and if the assets of
the Company are insufficient to pay in full such amounts, then the entire assets to be distributed
to the holders of the Series B Preferred shall be ratably distributed among the holders in
accordance with the respective amounts that would be payable on such shares if all amounts payable
thereon were paid in full.
Conversion; Conversion Price; Forced Conversion; Optional Redemption
Each share of Series B Preferred is convertible into a number of shares of Common Stock equal
to (1) the stated value of the share ($1,000), divided by (2) $0.60, subject to adjustment as
discussed below (the Conversion Price).
With certain exceptions, if, at any time while the Series B Preferred is outstanding, the
Company sells or grants any option to purchase or sells or grants any right to reprice, or
otherwise disposes of or issues (or announces any sale, grant or any option to purchase or other
disposition), any Common Stock or Common Stock equivalents at an effective price per share that is
lower than the then Conversion Price, then the Conversion Price will be reduced to equal the lower
price. The Conversion Price is also subject to proportional adjustment in the event of any stock
split, stock dividend, reclassification or similar event with respect to the Common Stock.
Commencing six months from the date of the Purchase Agreement, if the volume weighted average
price for each of any 20 consecutive trading days exceeds 200% of the then effective Conversion
Price and various other equity conditions are satisfied (including that the resale of the shares
underlying the Series B Preferred has been registered under the Securities Act), upon 30 days
notice, the Series B Preferred plus all accrued and unpaid dividends will automatically convert
into shares of Common Stock.
Commencing two years from the date of the Purchase Agreement, upon 30 days notice and provided
various other equity conditions are satisfied (including that the resale of the shares underlying
the Series B Preferred has been registered under the Securities Act), the Company may redeem some
or all of the then outstanding Series B Preferred for cash in an amount equal to the 150% of the
stated value of the Series B Preferred.
Voting
The holders of the Series B Preferred have no voting rights except with respect to specified
matters affecting the rights of the Series B Preferred.
Negative Covenants
As long as any shares of Series B Preferred are outstanding, the Company may not, directly or
indirectly: (a) amend its charter documents in any manner that materially and adversely affects any
rights of the holders of the Series B Preferred; (b) pay cash dividends or distributions on junior
securities of the Company (including the Common Stock); or (c) enter into any transaction with any
affiliate of the Company which would be required to be disclosed in any public filing, unless such
transaction is made on an arms-length basis and expressly approved by a majority of the
disinterested directors of the Company.
Triggering Events
In the event of a Triggering Event (as defined in the Certificate of Designation and described
below), any holder of Series B Preferred may require the Company to redeem all of its Series B
Preferred, at a redemption price equal to the greater of (a) 130% of the stated value and (b) the
product of (i) the volume weighted average price on the trading day immediately preceding the date
of the Triggering Event and (ii) the stated value divided by the then Conversion Price, plus all
accrued but unpaid dividends thereon and all liquidated damages and other costs, expenses or
amounts due in respect of the Series B Preferred. Triggering Events include, among other things,
bankruptcy related events, change of control transactions (as defined in the Certificate of
Designation), and various types of failures to perform under, and breaches of, the transaction
documents.
The form of Certificate of Designation is set forth in Exhibit 3.1.
Warrants
Each of the Warrants is exercisable upon issuance and expires on the fifth anniversary of
issuance. The initial exercise price of the Warrants is $0.8054 per share. With certain exceptions,
if, at any time while the Warrants
are outstanding, the Company sells or grants any option to purchase or sells or grants any right to
reprice, or otherwise disposes of or issues (or announces any sale, grant or any option to purchase
or other disposition), any Common Stock or Common Stock equivalents at an effective price per share
that is lower than the then exercise price of the relevant Warrant, then the exercise price of such
Warrant will be reduced to equal the lower price, and the number of shares issuable under the
Warrant be proportionately increased such that the aggregate exercise price payable, after taking
into account the decrease in the exercise price, shall be equal to the aggregate exercise price
prior to such adjustment.
The form of Warrant for the Transactions is attached hereto as Exhibit 4.1.
Registration Rights Agreement
In connection with the Purchase Agreement, the Company also entered into Registration Rights
Agreements with the Purchasers, which requires the Company to register the resale of the shares of
Common Stock underlying the Series B Preferred Stock, the shares of Common Stock underlying the
Warrants and, at the Companys options, all shares of Common Stock issuable as dividends on the
Series B Preferred. The Company is required to file the registration statement within the time
periods set forth in the agreement and the registration statement must be declared effective within
90 days of filing date (120 days if the registration statement is fully reviewed by the SEC), or
the Company will be required to pay liquidated damages as set forth in the agreement.
The form of the Registration Rights Agreement used for the Transactions is attached hereto as
Exhibit 10.2.
The above description of the material terms of the Transactions is qualified in its entirety
by reference to the documents attached hereto as Exhibits 3.1, 4.1, 10.1, and 10.2, which are
incorporated herein by reference.
December Private Placement
On December 8, 2010, Fibrocell Science, Inc. (the Company) completed a private placement of
securities in which the Company sold to certain accredited investors in the aggregate: (i) 165
shares of Series D Convertible Preferred Stock, with a par value of $0.001 per share and a stated
value of $1,000 per share (Series D Preferred), and (ii) warrants to purchase 330,000 shares of
Company common stock (Common Stock) at an exercise price of $0.50 per share (the Warrants) (the
Transactions).
The aggregate purchase price paid by the Purchasers for the Series D Preferred and the
Warrants was $165,000 (representing $1,000 for each share of Series D Preferred together with
Warrants). The Company intends to use the proceeds for working capital purposes.
Viriathus Capital LLC and John Carris Investments LLC were co-placement agents for the
Transactions, and received cash compensation of $13,200 and warrants to purchase 26,400 shares of
Common Stock at an exercise price of $0.50 per share (assuming all subscription proceeds are
received in the Transactions).
Terms of the Series D Preferred
To designate and establish the shares of Series D Preferred, the Companys Board of
Directors (the Board) approved, and on December 2, 2010, the Company filed with the Delaware
Secretary of State, a Certificate of Designation of Preferences, Rights and Limitations of Series D
Convertible Preferred Stock (the Certificate of Designation).
Dividends; Rank; Liquidation
Holders of the Series D Preferred are entitled to receive cumulative dividends at the rate per
share (as a percentage of the stated value per share) of 6% per annum (subject to increase in
certain circumstances), payable quarterly in arrears on January 15, April 15, July 15 and October
15, beginning on July 15, 2011. The dividends are payable in cash, or at the Companys option, in
duly authorized, validly issued, fully paid and non-assessable shares of Common Stock equal to 110%
of the cash dividend amount payable
on the dividend payment date, or a combination thereof; provided that the Company may not pay the dividends in shares of Common Stock
unless the Company meets certain conditions described in the Certificate of Designation, including
that the resale of the shares has been registered under the Securities Act of 1933, as amended (the
Securities Act) or is otherwise eligible to be resold pursuant to an exemption from the
Securities Act. If the Company pays the dividend in shares of Common Stock, the Common Stock will
be valued for such purpose at 80% of the average of the volume weighted average price for the 10
consecutive trading days ending on the trading day that is immediately prior to the dividend
payment date.
The Series D Preferred ranks senior to all shares of Common Stock, and junior to the Companys
Series A Convertible Preferred Stock and Series B Convertible Preferred Stock.
Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or
involuntary, the holders of the Series D Preferred shall be entitled to receive out of the assets,
whether capital or surplus, of the Company an amount equal to the stated value of the Common Stock,
plus any accrued and unpaid dividends thereon and any other fees or liquidated damages then due and
owing thereon under the Certificate of Designation, for each share of Series D Preferred before any
distribution or payment shall be made to the holders of any junior securities, and if the assets of
the Company are insufficient to pay in full such amounts, then the entire assets to be distributed
to the holders of the Series D Preferred shall be ratably distributed among the holders in
accordance with the respective amounts that would be payable on such shares if all amounts payable
thereon were paid in full.
Conversion; Conversion Price; Forced Conversion; Optional Redemption
Each share of Series D Preferred is convertible into a number of shares of Common Stock equal
to (1) the stated value of the share ($1,000), divided by (2) $0.50, subject to adjustment as
discussed below (the Conversion Price).
With certain exceptions, if, at any time while the Series D Preferred is outstanding, the
Company sells or grants any option to purchase or sells or grants any right to reprice, or
otherwise disposes of or issues (or announces any sale, grant or any option to purchase or other
disposition), any Common Stock or Common Stock equivalents at an effective price per share that is
lower than the then Conversion Price, then the Conversion Price will be reduced to equal the lower
price. The Conversion Price is also subject to proportional adjustment in the event of any stock
split, stock dividend, reclassification or similar event with respect to the Common Stock.
Commencing six months from the date of the acquisition of the Series D Preferred, if the
volume weighted average price for each of any 20 consecutive trading days exceeds 200% of the then
effective Conversion Price and various other equity conditions are satisfied (including that the
resale of the shares underlying the Series D Preferred has been registered under the Securities
Act), upon 30 days notice, the Series D Preferred plus all accrued and unpaid dividends will
automatically convert into shares of Common Stock.
Commencing two years from the date of the acquisition of the Series D Preferred, upon 30 days
notice and provided various other equity conditions are satisfied (including that the resale of the
shares underlying the Series D Preferred has been registered under the Securities Act), the Company
may redeem some or all of the then outstanding Series D Preferred for cash in an amount equal to
the 150% of the stated value of the Series D Preferred.
Voting
The holders of the Series D Preferred have no voting rights except with respect to specified
matters affecting the rights of the Series D Preferred.
Negative Covenants
As long as any shares of Series D Preferred are outstanding, the Company may not, directly or
indirectly: (a) amend its charter documents in any manner that materially and adversely affects any
rights of the holders of the Series D Preferred; (b) pay cash dividends or distributions on junior
securities of the Company (including the Common Stock); or (c) enter into any transaction with any
affiliate of the Company which would be required to be
disclosed in any public filing, unless such transaction is made on an arms-length basis and
expressly approved by a majority of the disinterested directors of the Company.
Triggering Events
In the event of a Triggering Event (as defined in the Certificate of Designation and described
below), any holder of Series D Preferred may require the Company to redeem all of its Series D
Preferred, at a redemption price equal to the greater of (a) 130% of the stated value and (b) the
product of (i) the volume weighted average price on the trading day immediately preceding the date
of the Triggering Event and (ii) the stated value divided by the then Conversion Price, plus all
accrued but unpaid dividends thereon and all liquidated damages and other costs, expenses or
amounts due in respect of the Series D Preferred. Triggering Events include, among other things,
bankruptcy related events, change of control transactions (as defined in the Certificate of
Designation), and various types of failures to perform under, and breaches of, the transaction
documents.
The form of Certificate of Designation is set forth in Exhibit 3.2.
Warrants
Each of the Warrants is exercisable upon issuance and expires on the fifth anniversary of
issuance. The initial exercise price of the Warrants is $0.50 per share. With certain exceptions,
if, at any time while the Warrants are outstanding, the Company sells or grants any option to
purchase or sells or grants any right to reprice, or otherwise disposes of or issues (or announces
any sale, grant or any option to purchase or other disposition), any Common Stock or Common Stock
equivalents at an effective price per share that is lower than the then exercise price of the
relevant Warrant, then the exercise price of such Warrant will be reduced to equal the lower price,
and the number of shares issuable under the Warrant be proportionately increased such that the
aggregate exercise price payable, after taking into account the decrease in the exercise price,
shall be equal to the aggregate exercise price prior to such adjustment.
The form of Warrant for the Transactions is attached hereto as Exhibit 4.1.
The above description of the material terms of the Transactions is qualified in its entirety
by reference to the documents attached hereto as Exhibits 3.2, 4.1, and 10.1, which are
incorporated herein by reference.
Effect of Series D Preferred Private Placement on Other Company Securities
As a result of the Series D Preferred private placement, anti-dilution provisions of other Company
securities were triggered, and as a result the following adjustments were made effective December
8, 2010.
Conversion Price Series A Preferred Stock and Series B Preferred Stock
Section 7(b) of the Certificates of Designation for the Series A Preferred Stock and Series B
Preferred Stock requires that the Conversion Price for the Series A Preferred Stock and Series B
Preferred Stock be reduced to equal the price per share of the common stock sold in the Offering.
Accordingly, the Conversion Price for the Series A Preferred Stock and Series B Preferred Stock is
being reduced to $0.50.
Convertible Shares Series A Preferred Stock and Series B Preferred Stock
Section 6(a) of the Certificates of Designation for the Series A Preferred Stock and Series B
Preferred Stock states that each share of Preferred Stock is convertible into that number of shares
of common stock determined by dividing the Stated Value of such share of Preferred Stock
(currently, $1,000 per share) by the Conversion Price. Accordingly, each investors Series A
Preferred Stock and Series B Preferred Stock may be converted into the number of shares of common
stock equal to ($1,000/.50) multiplied by the number of shares held by the investor. After giving
effect to this anti-dilution provision, there will be (i) 6,500,000 shares of Series A Preferred
Stock outstanding and (ii) 9,280,000 shares of Series B Preferred Stock outstanding.
As used below, Warrants refers to the following Company warrants: (i) the Series A and Series B
warrants issued in connection with the Series A Preferred Stock, (ii) the warrants issued in
connection with the Companys March 2010 offering, and (iii) the warrants issued in connection with
the Companys Series B Preferred Stock.
Exercise Price Warrants
Section 3(b) of the Warrants requires that the Exercise Price for the Warrants be reduced to equal
the price per share of the common stock sold in the Offering. Accordingly, the Exercise Price for
all of the Warrants is being reduced to $0.50.
Underlying Shares Warrants
Section 3(b) of the Warrants requires that the number of shares of common stock underlying the
Warrants (the Warrant Shares) be increased such that the aggregate exercise price following the
exercise price adjustment equals the aggregate exercise price prior to the exercise price
adjustment. As a result of this adjustment, the number of shares underlying each investors
Warrant will increase to equal the number of shares underlying the respective warrant multiplied by
the exercise price prior to dilution, divided by $0.50. After giving effect to this anti-dilution
provision, there will be:
| 1,624,996 shares of common stock underlying the Series A warrants; |
| 1,624,997 shares of common stock underlying the Series B warrants; |
| 9,950,261 shares of common stock underlying the warrants issued in connection with our
March 2010 Offering; and |
| 12,456,852 shares of common stock underlying the warrants issued in connection with our
Series B Offering. |
Item 3.02. Unregistered Sales of Equity Securities
The information contained in Item 1.01 is hereby incorporated by reference. The Series B
Preferred, the Series D Preferred and the Warrants were sold in transactions exempt from
registration under the Securities Act of 1933, in reliance on Section 4(2) thereof and Rule 506 of
Regulation D thereunder. Each Purchaser represented that it was an accredited investor as defined
in Regulation D.
Item 8.01
In the Companys Form 10-Q filed on November 15, 2010, the Company disclosed that in
connection with its September 2010 offering of Series B Preferred and Warrants, the Company had not
received $450,000 in subscription proceeds representing 450 shares Series B Preferred and Warrants
to purchase 750,000 shares. On November 17, 2010, the Company entered into a Termination Agreement
with the two Subscribers terminating their Securities Purchase Agreements with the Company.
Pursuant to the Termination Agreement, the two Subscribers are no longer liable to the Company for
the $450,000 subscription amount.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
Exhibit No. | Exhibit | |||
3.1 | Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible
Preferred Stock, dated July 16, 2010 (incorporated by reference to Exhibit 3.1 of the Form 8-K
filed July 19, 2010). |
|||
3.2 | Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of
Series D Convertible Preferred Stock, dated December 8, 2010. |
|||
4.1 | Form of Common Stock Purchase Warrant used for the Transactions (incorporated by reference to
Exhibit 4.1 of the Form 8-K filed October 22, 2010). |
|||
10.1 | Form of Securities Purchase Agreement used for the Transactions (incorporated by reference to
Exhibit 4.1 of the Form 8-K filed October 22, 2010). |
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
FIBROCELL SCIENCE, INC. |
||||
Date: December 27, 2010 | By: | /s/ Declan Daly | ||
Declan Daly, | ||||
Chief Operating Officer | ||||